{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:01:45Z","timestamp":1773813705770,"version":"3.50.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00415-025-13520-3","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T05:26:36Z","timestamp":1766553996000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of Rituximab in rElapsiNg Multiple SclErosis previously treated with hiGhly-Active Disease modifying thErapies (RENEGADE study)"],"prefix":"10.1007","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1607-543X","authenticated-orcid":false,"given":"Clara Grazia","family":"Chisari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Lo Fermo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Di Sapio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Pia","family":"Amato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Salemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Pesci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Curti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Ferraro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Lugaresi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Massacesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matilde","family":"Inglese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Gazzola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Realmuto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Fioretti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umberto","family":"Aguglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Montepietra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6923-0846","authenticated-orcid":false,"given":"Francesco","family":"Patti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the Italian Multiple Sclerosis and Related Disorders Register Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"issue":"6","key":"13520_CR1","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.autrev.2017.04.010","volume":"16","author":"B Merkel","year":"2017","unstructured":"Merkel B, Butzkueven H, Traboulsee AL, Havrdova E, Kalincik T (2017) Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: a systematic review. Autoimmun Rev 16(6):658\u2013665","journal-title":"Autoimmun Rev"},{"issue":"5","key":"13520_CR2","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1474-4422(07)70078-9","volume":"6","author":"L Kappos","year":"2007","unstructured":"Kappos L, Bates D, Hartung HP, Havrdova E, Miller D, Polman CH et al (2007) Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 6(5):431\u2013441","journal-title":"Lancet Neurol"},{"issue":"17","key":"13520_CR3","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1212\/WNL.0000000000000355","volume":"82","author":"RJ Fox","year":"2014","unstructured":"Fox RJ, Cree BA, De Seze J, Gold R, Hartung HP, Jeffery D et al (2014) MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology 82(17):1491\u20131498","journal-title":"Neurology"},{"issue":"21","key":"13520_CR4","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1212\/WNL.0b013e31823c1200","volume":"77","author":"KW Rammohan","year":"2011","unstructured":"Rammohan KW, Ortega MR, Delgado SR, Tornes L (2011) Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 77(21):1930 (discussion -1)","journal-title":"Neurology"},{"issue":"3","key":"13520_CR5","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/ana.22083","volume":"68","author":"JR Berger","year":"2010","unstructured":"Berger JR, Centonze D, Comi G, Confavreux C, Cutter G, Giovannoni G et al (2010) Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. Ann Neurol 68(3):409\u2013411","journal-title":"Ann Neurol"},{"issue":"5","key":"13520_CR6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217303","volume":"14","author":"E Evdoshenko","year":"2019","unstructured":"Evdoshenko E, Stepanova A, Shumilina M, Davydovskaya M, Khachanova N, Neofidov N et al (2019) Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia. PLoS ONE 14(5):e0217303","journal-title":"PLoS ONE"},{"issue":"15","key":"13520_CR7","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/s12883-015-0512-0","volume":"7","author":"F Patti","year":"2015","unstructured":"Patti F, Leone C, Zappia M (2015) Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report. BMC Neurol 7(15):252","journal-title":"BMC Neurol"},{"issue":"8","key":"13520_CR8","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1111\/ene.12195","volume":"20","author":"AP Sempere","year":"2013","unstructured":"Sempere AP, Berenguer-Ruiz L, Feliu-Rey E (2013) Rebound of disease activity during pregnancy after withdrawal of fingolimod. Eur J Neurol 20(8):e109\u2013e110","journal-title":"Eur J Neurol"},{"issue":"2","key":"13520_CR9","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1001\/archneurol.2011.1057","volume":"69","author":"JB Havla","year":"2012","unstructured":"Havla JB, Pellkofer HL, Meinl I, Gerdes LA, Hohlfeld R, Kumpfel T (2012) Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment. Arch Neurol 69(2):262\u2013264","journal-title":"Arch Neurol"},{"issue":"3","key":"13520_CR10","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.msard.2012.11.001","volume":"2","author":"RG Beran","year":"2013","unstructured":"Beran RG, Hegazi Y, Schwartz RS, Cordato DJ (2013) Rebound exacerbation multiple sclerosis following cessation of oral treatment. Multiple Scler Relat Disord 2(3):252\u2013255","journal-title":"Multiple Scler Relat Disord"},{"key":"13520_CR11","first-page":"135245852092459","volume":"12","author":"G Arrambide","year":"2020","unstructured":"Arrambide G, Iacobaeus E, Amato MP, Derfuss T, Vukusic S, Hemmer B et al (2020) Aggressive multiple sclerosis (2): treatment. Multiple Scler 12:1352458520924595","journal-title":"Multiple Scler"},{"issue":"7","key":"13520_CR12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11940-021-00677-1","volume":"23","author":"A Simpson","year":"2021","unstructured":"Simpson A, Mowry EM, Newsome SD (2021) Early aggressive treatment approaches for multiple sclerosis. Curr Treat Options Neurol 23(7):19","journal-title":"Curr Treat Options Neurol"},{"issue":"2","key":"13520_CR13","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00415-021-10676-6","volume":"269","author":"CG Chisari","year":"2022","unstructured":"Chisari CG, Comi G, Filippi M, Paolicelli D, Iaffaldano P, Zaffaroni M et al (2022) PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study. J Neurol 269(2):933\u2013944","journal-title":"J Neurol"},{"issue":"13 Pt 2","key":"13520_CR14","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1212\/01.wnl.0000265393.03231.e5","volume":"70","author":"MM Vellinga","year":"2008","unstructured":"Vellinga MM, Castelijns JA, Barkhof F, Uitdehaag BM, Polman CH (2008) Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology 70(13 Pt 2):1150\u20131151","journal-title":"Neurology"},{"issue":"2","key":"13520_CR15","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1001\/archneurol.2010.257","volume":"68","author":"A Miravalle","year":"2011","unstructured":"Miravalle A, Jensen R, Kinkel RP (2011) Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol 68(2):186\u2013191","journal-title":"Arch Neurol"},{"issue":"3","key":"13520_CR16","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1177\/1352458510392098","volume":"17","author":"G Borriello","year":"2011","unstructured":"Borriello G, Prosperini L, Marinelli F, Fubelli F, Pozzilli C (2011) Observations during an elective interruption of natalizumab treatment: a post-marketing study. Multiple Scler 17(3):372\u2013375","journal-title":"Multiple Scler"},{"issue":"9","key":"13520_CR17","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1007\/s00415-011-5996-y","volume":"258","author":"J Havla","year":"2011","unstructured":"Havla J, Gerdes LA, Meinl I, Krumbholz M, Faber H, Weber F et al (2011) De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate. J Neurol 258(9):1665\u20131669","journal-title":"J Neurol"},{"issue":"3","key":"13520_CR18","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/ana.22163","volume":"68","author":"TW West","year":"2010","unstructured":"West TW, Cree BA (2010) Natalizumab dosage suspension: are we helping or hurting? Ann Neurol 68(3):395\u2013399","journal-title":"Ann Neurol"},{"issue":"1","key":"13520_CR19","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/1352458514549398","volume":"21","author":"HP Hartung","year":"2015","unstructured":"Hartung HP, Aktas O, Boyko AN (2015) Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis. Multiple Scler 21(1):22\u201334","journal-title":"Multiple Scler"},{"key":"13520_CR20","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000799","author":"J Brannigan","year":"2020","unstructured":"Brannigan J, Jones JL, Stacpoole SRL (2020) Severe paradoxical disease activation following alemtuzumab treatment for multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.1212\/NXI.0000000000000799","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13520_CR21","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3389\/fneur.2019.00253","volume":"10","author":"K Barclay","year":"2019","unstructured":"Barclay K, Carruthers R, Traboulsee A, Bass AD, LaGanke C, Bertolotto A et al (2019) Best practices for long-term monitoring and follow-up of alemtuzumab-treated MS patients in real-world clinical settings. Front Neurol 10:253","journal-title":"Front Neurol"},{"key":"13520_CR22","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10354-022-00931-4","volume":"172","author":"T Moser","year":"2022","unstructured":"Moser T, Ziemssen T, Sellner J (2022) Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety. Wien Med Wochenschr 172:365\u2013372","journal-title":"Wien Med Wochenschr"},{"issue":"9","key":"13520_CR23","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.1007\/s12325-021-01865-w","volume":"38","author":"G Giovannoni","year":"2021","unstructured":"Giovannoni G, Comi G, Rammohan K, Rieckmann P, Dangond F, Keller B et al (2021) Long-term disease stability assessed by the expanded disability status scale in patients treated with cladribine tablets 3.5 mg\/kg for relapsing multiple sclerosis: an exploratory post hoc analysis of the CLARITY and CLARITY extension studies. Adv Ther 38(9):4975\u20134985","journal-title":"Adv Ther"},{"issue":"3","key":"13520_CR24","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1007\/s13311-021-01048-z","volume":"18","author":"ES Frisch","year":"2021","unstructured":"Frisch ES, Pretzsch R, Weber MS (2021) A milestone in multiple sclerosis therapy: monoclonal antibodies against CD20-yet progress continues. Neurotherapeutics 18(3):1602\u20131622","journal-title":"Neurotherapeutics"},{"issue":"1","key":"13520_CR25","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00415-020-10362-z","volume":"269","author":"CG Chisari","year":"2022","unstructured":"Chisari CG, Sgarlata E, Arena S, Toscano S, Luca M, Patti F (2022) Rituximab for the treatment of multiple sclerosis: a review. J Neurol 269(1):159\u2013183","journal-title":"J Neurol"},{"issue":"20","key":"13520_CR26","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1212\/WNL.0000000000003331","volume":"87","author":"J Salzer","year":"2016","unstructured":"Salzer J, Svenningsson R, Alping P, Novakova L, Bjorck A, Fink K et al (2016) Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy. Neurology 87(20):2074\u20132081","journal-title":"Neurology"},{"issue":"4","key":"13520_CR27","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ana.21867","volume":"66","author":"K Hawker","year":"2009","unstructured":"Hawker K, O\u2019Connor P, Freedman MS, Calabresi PA, Antel J, Simon J et al (2009) Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 66(4):460\u2013471","journal-title":"Ann Neurol"},{"key":"13520_CR28","doi-asserted-by":"crossref","first-page":"175628642412843","DOI":"10.1177\/17562864241284372","volume":"17","author":"C Oreja-Guevara","year":"2024","unstructured":"Oreja-Guevara C, Martinez-Yelamos S, Eichau S, Llaneza MA, Martin-Martinez J, Pena-Martinez J et al (2024) Beyond lines of treatment: embracing early high-efficacy disease-modifying treatments for multiple sclerosis management. Ther Adv Neurol Disord 17:17562864241284372","journal-title":"Ther Adv Neurol Disord"},{"key":"13520_CR29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.661882","volume":"12","author":"S Brancati","year":"2021","unstructured":"Brancati S, Gozzo L, Longo L, Vitale DC, Drago F (2021) Rituximab in multiple sclerosis: are we ready for regulatory approval? Front Immunol 12:661882","journal-title":"Front Immunol"},{"key":"13520_CR30","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2017","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G et al (2017) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17:162\u2013173","journal-title":"Lancet Neurol"},{"issue":"9","key":"13520_CR31","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","volume":"77","author":"L Kappos","year":"2020","unstructured":"Kappos L, Wolinsky JS, Giovannoni G, Arnold DL, Wang Q, Bernasconi C et al (2020) Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol 77(9):1132\u20131140","journal-title":"JAMA Neurol"},{"key":"13520_CR32","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/ana.27093","volume":"97","author":"N Montobbio","year":"2024","unstructured":"Montobbio N, Cordioli C, Signori A, Bovis F, Capra R, Sormani MP (2024) Relapse-associated and relapse-independent contribution to overall expanded disability status scale progression in multiple sclerosis patients diagnosed in different eras. Ann Neurol 97:95\u2013103","journal-title":"Ann Neurol"},{"issue":"1","key":"13520_CR33","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209444","volume":"103","author":"O Ciccarelli","year":"2024","unstructured":"Ciccarelli O, Barkhof F, Calabrese M, De Stefano N, Eshaghi A, Filippi M et al (2024) Using the progression independent of relapse activity framework to unveil the pathobiological foundations of multiple sclerosis. Neurology 103(1):e209444","journal-title":"Neurology"},{"issue":"1","key":"13520_CR34","volume":"7","author":"HM Torgauten","year":"2021","unstructured":"Torgauten HM, Myhr KM, Wergeland S, Bo L, Aarseth JH, Torkildsen O (2021) Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis\u2014a cohort study. Multiple Scler J Exp Transl Clin 7(1):2055217320973049","journal-title":"Multiple Scler J Exp Transl Clin"},{"issue":"5","key":"13520_CR35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197415","volume":"13","author":"B Scotti","year":"2018","unstructured":"Scotti B, Disanto G, Sacco R, Guigli M, Zecca C, Gobbi C (2018) Effectiveness and safety of Rituximab in multiple sclerosis: an observational study from Southern Switzerland. PLoS ONE 13(5):e0197415","journal-title":"PLoS ONE"},{"issue":"3","key":"13520_CR36","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1001\/jamaneurol.2018.4239","volume":"76","author":"Y Naegelin","year":"2019","unstructured":"Naegelin Y, Naegelin P, von Felten S, Lorscheider J, Sonder J, Uitdehaag BMJ et al (2019) Association of rituximab treatment with disability progression among patients with secondary progressive multiple sclerosis. JAMA Neurol 76(3):274\u2013281","journal-title":"JAMA Neurol"},{"key":"13520_CR37","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/725370","volume":"2015","author":"L Haider","year":"2015","unstructured":"Haider L (2015) Inflammation, iron, energy failure, and oxidative stress in the pathogenesis of multiple sclerosis. Oxid Med Cell Longev 2015:725370","journal-title":"Oxid Med Cell Longev"},{"key":"13520_CR38","volume":"71","author":"AU Fakih","year":"2023","unstructured":"Fakih AU, Sahraian MA, Paybast S, Naser Moghadasi A (2023) Effectiveness and safety of switching from fingolimod and natalizumab to rituximab in patients with relapsing remitting multiple sclerosis. Multiple Scler Relat Disord 71:104564","journal-title":"Multiple Scler Relat Disord"},{"key":"13520_CR39","unstructured":"Meglio M (2023) Anti-CD20 therapies shown to be effective after switch from natalizumab. In: ECTRIMS 2023."},{"key":"13520_CR40","doi-asserted-by":"crossref","first-page":"175628641983780","DOI":"10.1177\/1756286419837809","volume":"12","author":"L Prosperini","year":"2019","unstructured":"Prosperini L, Kinkel RP, Miravalle AA, Iaffaldano P, Fantaccini S (2019) Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis. Ther Adv Neurol Disord 12:1756286419837809","journal-title":"Ther Adv Neurol Disord"},{"issue":"6","key":"13520_CR41","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000297","volume":"3","author":"C Papeix","year":"2016","unstructured":"Papeix C, Vukusic S, Casey R, Debard N, Stankoff B, Mrejen S et al (2016) Risk of relapse after natalizumab withdrawal: results from the French TYSEDMUS cohort. Neurol Neuroimmunol Neuroinflamm 3(6):e297","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"6","key":"13520_CR42","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/ana.24651","volume":"79","author":"P Alping","year":"2016","unstructured":"Alping P, Frisell T, Novakova L, Islam-Jakobsson P, Salzer J, Bjorck A et al (2016) Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Ann Neurol 79(6):950\u2013958","journal-title":"Ann Neurol"},{"issue":"3","key":"13520_CR43","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s13365-018-0615-7","volume":"24","author":"JR Berger","year":"2018","unstructured":"Berger JR, Malik V, Lacey S, Brunetta P, Lehane PB (2018) Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event. J Neurovirol 24(3):323\u2013331","journal-title":"J Neurovirol"},{"issue":"6","key":"13520_CR44","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1177\/1352458518772748","volume":"25","author":"P Durozard","year":"2019","unstructured":"Durozard P, Maarouf A, Boutiere C, Ruet A, Brochet B, Vukusic S et al (2019) Efficacy of rituximab in refractory RRMS. Multiple Scler 25(6):828\u2013836","journal-title":"Multiple Scler"},{"issue":"2","key":"13520_CR45","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40120-015-0038-9","volume":"4","author":"M Lo Re","year":"2015","unstructured":"Lo Re M, Capobianco M, Ragonese P, Realmuto S, Malucchi S, Berchialla P et al (2015) Natalizumab discontinuation and treatment strategies in patients with multiple sclerosis (MS): a retrospective study from two Italian MS centers. Neurol Ther 4(2):147\u2013157","journal-title":"Neurol Ther"},{"key":"13520_CR46","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.msard.2018.07.005","volume":"25","author":"Y Naegelin","year":"2018","unstructured":"Naegelin Y, Rasenack M, Andelova M, Von Felten S, Fischer-Barnicol B, Amann M et al (2018) Shortening the washout to 4 weeks when switching from natalizumab to fingolimod and risk of disease reactivation in multiple sclerosis. Multiple Scler Relat Disord 25:14\u201320","journal-title":"Multiple Scler Relat Disord"},{"key":"13520_CR47","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3389\/fimmu.2019.00201","volume":"10","author":"S Hausser-Kinzel","year":"2019","unstructured":"Hausser-Kinzel S, Weber MS (2019) The role of B cells and antibodies in multiple sclerosis, neuromyelitis optica, and related disorders. Front Immunol 10:201","journal-title":"Front Immunol"},{"issue":"1","key":"13520_CR48","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ana.25927","volume":"89","author":"G Comi","year":"2021","unstructured":"Comi G, Bar-Or A, Lassmann H, Uccelli A, Hartung HP, Montalban X et al (2021) Role of B cells in multiple sclerosis and related disorders. Ann Neurol 89(1):13\u201323","journal-title":"Ann Neurol"},{"key":"13520_CR49","volume":"62","author":"GO Nygaard","year":"2022","unstructured":"Nygaard GO, Torgauten H, Skattebol L, Hogestol EA, Sowa P, Myhr KM et al (2022) Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis. Multiple Scler Relat Disord 62:103812","journal-title":"Multiple Scler Relat Disord"},{"key":"13520_CR50","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200152","author":"R Claverie","year":"2023","unstructured":"Claverie R, Perriguey M, Rico A, Boutiere C, Demortiere S, Durozard P et al (2023) Efficacy of rituximab outlasts B-cell repopulation in multiple sclerosis: time to rethink dosing? Neurol Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.1212\/NXI.0000000000200152","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"9","key":"13520_CR51","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","volume":"72","author":"RF van Vollenhoven","year":"2013","unstructured":"van Vollenhoven RF, Emery P, Bingham CO Jr, Keystone EC, Fleischmann RM, Furst DE et al (2013) Long-term safety of rituximab in rheumatoid arthritis: 95-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 72(9):1496\u20131502","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"13520_CR52","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1212\/CPJ.0000000000001177","volume":"12","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Cofield S, Cutter G, Krieger S, Wolinsky JS, Lublin F (2022) Predictors of disease activity and worsening in relapsing-remitting multiple sclerosis. Neurol Clin Pract 12(4):e58\u2013e65","journal-title":"Neurol Clin Pract"},{"issue":"3","key":"13520_CR53","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00415-023-12132-z","volume":"271","author":"M Andorra","year":"2024","unstructured":"Andorra M, Freire A, Zubizarreta I, de Rosbo NK, Bos SD, Rinas M et al (2024) Predicting disease severity in multiple sclerosis using multimodal data and machine learning. J Neurol 271(3):1133\u20131149","journal-title":"J Neurol"},{"key":"13520_CR54","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200056","author":"C Starvaggi Cucuzza","year":"2023","unstructured":"Starvaggi Cucuzza C, Longinetti E, Ruffin N, Evertsson B, Kockum I, Jagodic M et al (2023) Sustained low relapse rate with highly variable B-cell repopulation dynamics with extended rituximab dosing intervals in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.1212\/NXI.0000000000200056","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"13520_CR55","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00415-023-11969-8","volume":"271","author":"K Selmaj","year":"2024","unstructured":"Selmaj K, Cree BAC, Barnett M, Thompson A, Hartung HP (2024) Multiple sclerosis: time for early treatment with high-efficacy drugs. J Neurol 271(1):105\u2013115","journal-title":"J Neurol"},{"key":"13520_CR56","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S1474-4422(22)00209-5","volume":"21","author":"A Svenningsson","year":"2022","unstructured":"Svenningsson A, Frisell T, Burman J, Salzer J, Fink K, Hallberg S et al (2022) Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial. Lancet Neurol 21:693\u2013703. https:\/\/doi.org\/10.1016\/S1474-4422(22)00209-5","journal-title":"Lancet Neurol"},{"issue":"6","key":"13520_CR57","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/ana.26914","volume":"95","author":"P Alping","year":"2024","unstructured":"Alping P, Neovius M, Piehl F, Frisell T (2024) Real-world healthcare cost savings and reduced relapse rate with off-label rituximab versus disease-modifying treatments approved for relapsing-remitting multiple sclerosis: a nationwide cost-effectiveness study. Ann Neurol 95(6):1099\u20131111","journal-title":"Ann Neurol"},{"issue":"8","key":"13520_CR58","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/jamaneurol.2023.1625","volume":"80","author":"I Roos","year":"2023","unstructured":"Roos I, Hughes S, McDonnell G, Malpas CB, Sharmin S, Boz C et al (2023) Rituximab vs ocrelizumab in relapsing-remitting multiple sclerosis. JAMA Neurol 80(8):789\u2013797","journal-title":"JAMA Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13520-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13520-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13520-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T05:04:41Z","timestamp":1773810281000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13520-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["13520"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13520-3","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"16 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Clara G. Chisari reported receiving grants to attend scientific congresses or speaker honoraria from Biogen, Merck-Serono, Novartis, Roche, Sanofi\/Genzyme, Teva. Salvatore Lo Fermo reported no disclosures. Alessia Di Sapio reported no disclosures. Maria Pia Amato reported no disclosures. Giuseppe Salemi reported no disclosures. Ilaria Pesci reported no disclosures. Erica Curti reported no disclosures. Diana Ferraro reported no disclosures. Alessandra Lugaresi has received personal compensation from Alexion, Amgen\/Horizon, Biogen, Bristol Myers Squibb\/Celgene, Janssen\/Johnson&Johnson, Merck Serono, Novartis, Roche, Sanofi\/Genzyme and Fondazione Italiana Sclerosi Multipla (FISM). Her institutions received research grants from Novartis, Roche and Sanofi\/Genzyme. Luca Massacesi reported no disclosures. Matilde Inglese reported no disclosures. Paola Gazzola reported no disclosures. Sabrina Realmuto reported no disclosures. Cristina Fioretti reported no disclosures. Umberto Aguglia reported no disclosures. Sara Montepietra reported no disclosures. Massimo Filippi received compensation for consulting services from Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi, speaking activities from Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA, participation in Advisory Boards for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda, scientific direction of educational events for Biogen, Merck, Roche, Celgene, Bristol-Myers Squibb, Lilly, Novartis, Sanofi-Genzyme, he receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla. Francesco Patti reported receiving honoraria for speaking activities by Almirall, Bayer Schering, Biogen Idec, Merck Serono, Novartis, Roche, Sanofi Genzyme, and TEVA; he also served as advisory board member the following companies: Bayer Schering, Biogen Idec, Merck Serono, Novartis, Roche, Sanofi Genzyme, and TEVA; he was also funded by Pfizer and FISM for epidemiological studies; he received grants for congress participation from Almirall, Bayer Shering, Biogen Idec, Merck Serono, Novartis, Roche, Sanofi Genzyme, and TEVA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study protocol was approved by the local Ethical Committee of the University of Catania (Catania 1, Italy) and by the Ethical Committee of the participating centers. The study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Each patient participating to the study signed an Informed Consent specifically designed to participate to the study protocol.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"47"}}